Verbio's Green Chemistry Bet Meets a Bruised Stock

Verbio's stock plunges 9% amid high volatility, yet retains 291% yearly gain. Institutional interest and a new ethenolysis plant in Germany highlight long-term potential.

The disconnect between Verbio’s operational ambitions and its share price performance is widening. While the biofuels and green chemicals specialist unveils its latest innovations at the Chemspec Europe trade fair in Cologne, investors have been hitting the sell button with unusual force.

Shares in the German company tumbled nearly nine percent on Wednesday to €37.04, a sharp pullback that underscores the stock’s notoriously volatile character. The move comes just days after the stock had been trading at €40.46, a level that had briefly reignited optimism among institutional buyers.

A 291% gain — and still no rest

Despite the midweek sell-off, the longer-term picture remains striking. Since the start of 2024, Verbio shares have surged by more than 80 percent, while the twelve-month gain stands at an eye-watering 291 percent. That kind of performance has naturally attracted attention from big money. Market observers point to Union Investment as one institutional player currently building a position in the stock, a development that provided short-term support earlier this week.

The stock’s 50-day moving average sits at €35.66, meaning Wednesday’s close still leaves it comfortably above that technical threshold. But the path ahead is far from clear. After hitting a 52-week high of €46.14 in early April, the shares have entered a consolidation phase. Chart analysts now see the €34 zone as a key support level, while the April peak remains the next major resistance. Bernstein Research has set a price target of €40 — right where the stock was trading before the latest drop.

Volatility as a feature, not a bug

Verbio’s annualized volatility has exceeded 100 percent over the past 30 trading days, a figure that explains why moves of this magnitude have become almost routine. The Relative Strength Index has slipped to around 40, placing the stock in neutral-to-slightly-oversold territory — a technical setup that historically has preceded stabilization.

Whether the current recovery attempt gains traction depends largely on whether institutional buying proves sustained or merely opportunistic. The stock’s extreme swings in both directions make it a high-stakes game for traders and a headache for longer-term holders.

From rapeseed to revenue

Away from the noise of the trading floor, Verbio is pushing ahead with its most ambitious industrial project to date. At the heart of this strategy is a new ethenolysis plant under construction in Bitterfeld, Saxony-Anhalt. The facility, scheduled to begin operations in the second half of 2026, will use a proprietary technology to convert rapeseed methyl ester into renewable specialty chemicals.

At full capacity, the plant is expected to produce up to 60,000 tonnes of bio-based molecules annually. Critically, Verbio is keeping the entire value chain in-house: the required catalysts are developed and manufactured by its Hungarian subsidiary XiMo. This vertical integration is a key differentiator from competitors who rely on external suppliers.

The company is also showcasing new C10 building blocks and platform molecules at Chemspec Europe, all derived from locally sourced rapeseed oil. These compounds are used in lubricants, plastics, coatings, and adhesives — markets where European manufacturers are increasingly seeking alternatives to fossil-based inputs and long-distance supply chains.

What comes next

All eyes now turn to Verbio’s third-quarter results, due for release in May. The report will offer the first concrete look at how the company’s core biofuels business is performing amid volatile energy markets and shifting regulatory landscapes. Strong margins could quickly put the recent share price weakness into perspective — but with volatility this high, no outcome can be taken for granted.